NRX Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview

NRX Pharmaceuticals

26/03/2024 20:24

* NRX Pharmaceuticals Inc  NRXP.OQ   NRXP.O  is expected
to report
resultson March 28 for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for NRX Pharmaceuticals Inc
is for
a loss of 7 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NRX
Pharmaceuticals Inc is $2.00​, above​ its last closing price
of $0.53. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.12       -0.11      -0.07     Beat    38.2
 Jun. 30 2023  -0.15       -0.14      -0.12     Beat    12.2
 Mar. 31 2023  -0.14       -0.14      -0.16     Missed  -14.3​
 Dec. 31 2022              -0.14      -0.16     Missed  -10.3
 ​​Sep.        -0.14       -0.14      -0.14     Met     0
 30 2022                                                
 Jun. 30 2022  -0.10       -0.10      -0.11     Missed  -10​
 This summary was machine generated March 26 at 20:24 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)